Eureka Alert

RICHMOND, BC and GUILFORD, CONN., BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical-need, including brain cancers and neurodegenerative diseases, today announced the publication of independent research validating the ability of the company’s xB3 platform to efficiently deliver antibodies across the blood-brain barrier to the central nervous system in therapeutically relevant doses.

Scientists at MedImmune, the global biologics research and development arm of AstraZeneca, evaluated Bioasis’ xB3 platform technology by making two xB3 antibody fusion proteins and measuring systemic pharmacokinetic (PK) and brain exposure in mice; this was followed by a pharmacodynamic (PD) study in a mouse neuropathic pain model. This research shows that the xB3 platform demonstrated a strong PK/PD dose dependent relationship in this pre-clinical neuropathic pain mouse model without compromising peripheral pharmacokinetic properties. The research conducted by Thom, et al., “A peptide derived from melanotransferrin delivers a protein-based interleukin 1 receptor antagonist across the BBB and ameliorates neuropathic pain in a pre-clinical model,” was published in the Journal of Cerebral Blood Flow and Metabolism.

The study found that


Article originally posted at

Click here for the full story

CategoryAggregator News

Privacy Policy / Terms Of Use

Powered by MMD